12:00 AM
Apr 22, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

19-28z T cells: Phase I data

Researchers at the center and colleagues reported data from an open-label, U.S. Phase I trial showing that all 5 patients with relapsed B cell ALL that were treated with 19-28z autologous T cells achieved tumor eradication and complete remission. Of the 5 patients, 4 subsequently...

Read the full 203 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >